Lv11
20 积分 2023-07-25 加入
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N -Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
1小时前
已关闭
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
1个月前
已完结
Acacetin is a Promising Drug Candidate for Cardiovascular Diseases
1个月前
已完结
Prevalence of Elevated Lipoprotein(a) and its Association With Subclinical Atherosclerosis in 2.9 Million Chinese Adults
1个月前
已完结
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
2个月前
已完结
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
2个月前
已完结
Role of S100A1, S100A4, S100A8/A9 and S100B in myocardial infarction and heart failure
3个月前
已完结
Biological Significance of EphB4 Expression in Cancer
3个月前
已完结
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
4个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
4个月前
已完结
皖公网安备34019202002308
